✦ LIBER ✦

High dose tamoxifen plus cisplatin and etoposide in the treatment of patients with advanced, inoperable nonsmall cell lung carcinoma

✍ Scribed by Chih-Hsin Yang; Ann-Lii Cheng; Kun-Huei Yeh; Chong-Jen Yu; Jing-Fang Lin; Pan-Chyr Yang

Publisher: John Wiley and Sons
Year: 1999
Tongue: English
Weight: 74 KB
Volume: 86
Category: Article
ISSN: 0008-543X
DOI: 10.1002/(sici)1097-0142(19990801)86:3<415::aid-cncr9>3.0.co;2-h

No coin nor oath required. For personal study only.

✦ Synopsis

BACKGROUND.

Tamoxifen sensitizes cancer cells to chemotherapeutic agents. High dose tamoxifen has been tested in the treatment of patients with melanoma and other cancers. The authors conducted a Phase II study of high dose tamoxifen plus cisplatin and etoposide for patients with advanced, inoperable nonsmall cell lung carcinoma.

📜 SIMILAR VOLUMES

A phase II study of gemcitabine plus ora

A phase II study of gemcitabine plus oral etoposide in the treatment of patients with advanced nonsmall cell lung carcinoma

✍ Tony S. K. Mok; Benny Zee; Anthony T. C. Chan; Winnie Yeo; Wei Tse Yang; Anthony 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 95 KB 👁 2 views

UFT plus cisplatin combination chemother

UFT plus cisplatin combination chemotherapy in the treatment of patients with advanced nonsmall cell lung carcinoma : A multiinstitutional Phase II trial

✍ Yukito Ichinose; Kozo Yosimori; Shuichi Yoneda; Mutsuo Kuba; Shoji Kudoh; Hisano 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB 👁 2 views

## Background: Combination chemotherapy comprised of oral uft (a combination of tegafur and uracil) and cisplatin was shown to be an effective regimen for the treatment of advanced nonsmall cell lung carcinoma and to be associated with a low incidence rate of toxicity in a previous, single institut

Treatment of advanced non-small cell lun

Treatment of advanced non-small cell lung cancer with very high-dose cisplatin combined with etoposide and mitomycin C

✍ Paul J. Hesketh; Sualp Tansan; Priscilla B. Caguioa; Ann Hesketh; Rita Blanchard 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 428 KB 👁 1 views

A phase II trial of oral tegafur and ura

A phase II trial of oral tegafur and uracil plus cisplatin in patients with inoperable nonsmall cell lung cancer

✍ Yukito Ichinose; Nobuko Takanashi; Tokujiro Yano; Hiroshi Asoh; Hideki Yokoyama; 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 391 KB 👁 1 views

## Background: The combination of uracil and tegafur in a 4:1 molar concentration (uft) has a greater antitumor activity than 5-fluorouracil (5-fu) and tegafur. because the combination of 5-fu and cisplatin has been proven to have a synergistic antitumor effect in many experimental and clinical stu

Treatment of patients with advanced nons

Treatment of patients with advanced nonsmall cell lung carcinoma using docetaxel and gemcitabine plus granulocyte-colony stimulating factor

✍ Michael Hejna; Gabriela V. Kornek; Markus Raderer; Herbert Ulrich-Pur; Wolfgang 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 78 KB 👁 1 views

Increasing dose intensity of cisplatin-e

Increasing dose intensity of cisplatin-etoposide in advanced nonsmall cell lung carcinoma : A Phase III randomized trial of the Spanish lung cancer group

✍ Albert Font; Alfredo J. Moyano; Jose M. Puerto; Alejandro Tres; Carlos Garcia-Gi 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 97 KB 👁 2 views

## Background: The authors designed this randomized, controlled trial to assess whether dose intensification of a cisplatin-etoposide combination (pe), achieved by shortening the interval between chemotherapy cycles, would improve response rate and survival. the maximum tolerated dose of pe was adm